Funded Startups in Provence-Alpes-Cote D'azur
Among the 50 most recent funded startups in Provence-Alpes-Côte d’Azur shown here, Melvan’s $29M round (2025-06-25) is the largest disclosed amount; it sit…
Among the 50 most recent funded startups in Provence-Alpes-Côte d’Azur shown here, Melvan’s $29M round (2025-06-25) is the largest disclosed amount; it sits far above the next-largest disclosed rounds such as TSE’s $104M (2025-01-20) and higher-value biotech/health investments earlier in the window (e.g., Innate Pharma $17M on 2025-04-24). Another clear pattern is stage and disclosure mix: 22 of the 50 entries show “Series Unknown,” and 3 list an “undisclosed” amount (Guepard 2025-09-27; Green Praxis 2024-03-22; BuyCo 2023-07-24), making disclosed round sizes uneven across time. City-level clustering appears around Marseille and Aix-en-Provence (multiple entries across fintech, health, and data), while the temporal range spans from 2022-11-03 (Izicap) through 2025-09-27 (Guepard), with the most recent entries concentrated in late 2024 through 2025.
Most recent rounds
50 shownRelated listings
Frequently asked
Which disclosed round is the outlier by size, and how does it affect comparisons of “largest rounds” in this list?
TSE’s $104M (2025-01-20) is the top disclosed amount in the 50 rows, dwarfing other disclosed entries like DiogenX’s $30M (2023-05-10) and Melvan’s $29M (2025-06-25). Multiple rounds fall well below that level, including several in the $15M–$20M band (e.g., Innate Pharma $17M on 2025-04-24; Ecoat $20M on 2025-04-03), so size-based rankings are dominated by that one $104M event.
Do rounds cluster in time, especially in 2024–2025, or are they spread evenly across the three-year window?
The list spans 2022-11-03 (Izicap) to 2025-09-27 (Guepard), but many high-confidence disclosed rounds concentrate in 2025 (e.g., TSE $104M on 2025-01-20; Median Technologies $39M on 2025-01-24; Melvan $29M on 2025-06-25; A.M.A Selections $690K on 2025-08-28). Earlier years also have clusters, such as 2023-02-06 to 2023-04-11 with multiple seed-to-Series A financings (e.g., CryptoSimple $1M on 2023-02-06; Avicenna.ai $8M on 2023-02-08; Ilios International $1M on 2023-04-11).
Are any cities or metro areas over-represented across sectors like health, energy, and data?
Marseille shows up repeatedly across categories, including Innate Pharma (2025-04-24, $17M), Guepard (2025-09-27, undisclosed), DiogenX (2023-05-10, $30M), and Drivata (2023-03-14, undisclosed). Aix-en-Provence also recurs with multiple energy and fintech/data-adjacent entries such as TSE (Valbonne, 2025-01-20), Otrera (Aix-en-provence, 2024-12-04, $3M), Chargepoly (Aix-en-provence, 2023-10-13, $16M), and Abelio (Aix-en-provence, 2023-09-04, $2M).
What does the stage and disclosure mix suggest for how comparable the round sizes are?
A large share of entries do not provide a stage label: 22 of 50 are marked “Series Unknown” (for example, Melvan 2025-06-25 with $29M and Ecoat 2025-04-03 with $20M). Amounts are also partially missing: 3 entries are “undisclosed” (Guepard 2025-09-27; Green Praxis 2024-03-22; BuyCo 2023-07-24), so comparisons by both stage and disclosed size will be biased toward rows with reported amounts.
Which sectors appear most often, and are they driven by a few large rounds or many mid-sized ones?
Biotechnology appears frequently, including Innate Pharma ($17M on 2025-04-24), Ecoat ($20M on 2025-04-03), NicOx ($4M on 2024-07-18), DIAMIDEX ($3M on 2023-11-04), and DiogenX ($30M on 2023-05-10). Energy also recurs with multiple sizable financings (TSE $104M on 2025-01-20; Chargepoly $16M on 2023-10-13; Melvan $29M on 2025-06-25; Otrera $3M on 2024-12-04), meaning both large outliers and mid-sized rounds contribute to the sector footprint.
Which entries fall closest to the end of the date window (most recent 90 days in the list), based on the shown dates?
Using the latest date shown (2025-09-27), the most recent entries in that trailing window include Guepard (2025-09-27, undisclosed), A.M.A Selections (2025-08-28, $690K), Melvan (2025-06-25, $29M), Innate Pharma (2025-04-24, $17M), and Ecoat (2025-04-03, $20M). Several of these are biotech/energy-adjacent (e.g., Innate Pharma and Ecoat), while the disclosure mix is mixed (e.g., Guepard is undisclosed).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.